Lord, Abbett & Co
FBRX icon

Lord, Abbett & Co’s Forte Biosciences FBRX Stock Holding History

Lord, Abbett & Co’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.97M Buy
+114,635
New +$3.3M 0.01% 507

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Lord, Abbett & Co's FBRX Position: Q1 2026 in Review

Lord, Abbett & Co opened a new position in Forte Biosciences (FBRX) in Q1 2026: 114,635 shares worth $2.97M. The stake represents 0.01% of the portfolio and ranks #507 among its holdings.

68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • Lord, Abbett & Co held 114,635 shares of Forte Biosciences worth $2.97M as of Q1 2026.
  • Forte Biosciences was a new Lord, Abbett & Co position in Q1 2026.
  • Forte Biosciences made up 0.01% of Lord, Abbett & Co's portfolio in Q1 2026, its #507 holding.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on Lord, Abbett & Co's 13F filing for Q1 2026, filed 14 May 2026.